Phillip G. Febbo
Chief Medical Officer and Senior Vice President, Clinical Genomics, Illumina (USA)
Phil Febbo, joined Illumina as Chief Medical Officer (CMO) in March 2018.
For the past 25 years, Dr. Febbo has worked at leading Institutes throughout the United States, most recently serving as CMO of Genomic Health. Prior to Genomic Health, Phil served as Professor of Medicine and Urology at the University of California, San Francisco where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer and his clinical practice focused on genitourinary oncology. While at UCSF, Phil was the Co-Leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.
Phil holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at the University of California, San Francisco and completed Internal Medicine Residency at the Brigham and Women’ s Hospital in Boston, Massachusetts. After his fellowship in Medical Oncology at the Dana Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at the Dana Farber Cancer Institute, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub’s laboratory at the Dana Farber Cancer Institute as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute).
In 2004, Phil moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. In 2010, he returned to UCSF. Phil’s laboratory was funded by the NIH, DOD, Damon Runyon Cancer Research Foundation, and the Prostate Cancer Foundation. He has been a member of the American Society for Clinical Investigation since 2009.